Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
Dainippon Sumitomo Pharma (DSP) said on May 23 that it will discontinue a global PIII trial for its investigational anticancer drug BBI608 in patients with colorectal cancer following a recommendation from an independent safety monitoring committee. The trial, dubbed CO.23,…
To read the full story
Related Article
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
August 8, 2014
BUSINESS
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…